This technology involves the amalgamation of the rapidly evolving fields of nanotechnology and epigenetics. To target epimutations of the BRCA1 and/or BRCA2 genes from aberrant DNA demethylation, before a malignant breast cancer transformation occurs, an engineered gene that contains a DNA demethylase domain and a zinc finger domain will be used. This engineered gene will be transported to the breast cells via a liposome, a transporting vesicle composed of a lipid bilayer.